The landscape of American hospital finance is bracing for a significant shift as the Centers for Medicare & Medicaid Services (CMS) has unveiled its proposed 2027 Medicare Hospital Outpatient Prospective Payment System (OPPS) rule. At the center of this controversy is a radical restructuring of how Medicare reimburses hospitals for drugs procured through the 340B Drug Pricing Program.
If finalized, the proposal would slash Medicare’s reimbursement rate for 340B-acquired drugs from the current level of Average Sales Price (ASP) plus 6% to ASP minus 33.4%. This 37% reduction represents a seismic shift in federal policy, aimed—according to CMS—at aligning Medicare payments more closely with the actual acquisition costs incurred by hospitals. However, the proposal has ignited a firestorm of debate, pitting the federal government’s desire for fiscal efficiency against the financial stability of the nation’s safety-net providers.
Main Facts: The Anatomy of the Proposal
The 340B program, established by Congress in 1992, mandates that pharmaceutical manufacturers provide outpatient drugs to specific nonprofit and government-run hospitals at steep discounts. These hospitals, which serve high volumes of low-income and underserved populations, often rely on the spread between the discounted purchase price and the higher Medicare reimbursement rate to fund their broader mission, including uncompensated care and community health operations.
CMS’s latest move is explicitly designed to recalibrate this financial engine. The agency justifies the move by citing a 2026 cost acquisition survey, which suggested that current reimbursement levels significantly exceed the price hospitals actually pay for these drugs.
Key components of the 2027 proposal include:
- A 37% Payment Cut: Reducing reimbursement for 340B drugs to ASP minus 33.4%.
- Budget Neutrality Reallocation: Because federal law requires OPPS to remain budget-neutral, the $4.85 billion in projected savings from the 340B cuts will be redistributed as an 8.44% across-the-board increase in payments for non-drug outpatient services.
- Targeted Exemptions: Rural sole community hospitals (SCHs), children’s hospitals, and PPS-exempt cancer hospitals are shielded from the cuts to prevent destabilizing these specific niches.
A Brief Chronology of a Regulatory Battle
The attempt to reduce 340B reimbursement is not a new concept; it is the resurrection of a policy battlefield that has seen multiple turns over the last decade.
- 2018: The first Trump administration implemented a policy to reduce 340B payments to ASP minus 22.5%.
- 2022: The Supreme Court unanimously struck down the 2018 rule. The Court ruled that because the Department of Health and Human Services (HHS) had not conducted a formal survey of hospital acquisition costs, the cuts were illegal under the Medicare statute.
- Early 2026: In a bid to satisfy the Supreme Court’s mandate, CMS conducted an extensive cost acquisition survey of hospitals, providing the empirical foundation for the new proposal.
- July 2026: CMS officially released the 2027 proposed OPPS rule, signaling a renewed intent to lower payments using the new survey data.
- January 1, 2027 (Anticipated): The proposed implementation date for the new reimbursement structure.
Supporting Data and Financial Implications
The mechanics of this policy change reveal a complex redistribution of wealth within the hospital sector. Because the policy is bound by budget neutrality, it is effectively a "zero-sum" game where some facilities will see their bottom lines grow while others see them contract.
The Redistribution Effect
CMS estimates that while Medicare will save $4.85 billion on 340B drug spending, it will simultaneously spend an additional $4.85 billion on non-drug outpatient services. This means that hospitals heavily reliant on 340B drug revenue—primarily safety-net institutions—will face a net revenue decline. Conversely, hospitals with high volumes of non-drug outpatient services but lower utilization of 340B drugs—such as many for-profit surgical centers—stand to see a significant revenue boost.
Beneficiary Impact
For the average Medicare beneficiary, the effects are mixed. Patients who receive 340B-covered drugs will see lower cost-sharing requirements, as the 20% coinsurance will be calculated against a significantly lower base price. CMS projects these patients will save roughly $1.15 billion in 2027. However, the same patients, and others utilizing the outpatient system, will face increased out-of-pocket costs for non-drug services like imaging, minor surgeries, and laboratory tests due to the budget-neutrality-induced 8.44% rate hike.
Official Responses and Industry Sentiment
The hospital industry remains deeply divided. Large, for-profit health systems generally argue that the 340B program has suffered from "mission creep," with some hospitals acquiring small physician practices specifically to claim 340B discounts on drugs that have nothing to do with the original intent of serving the poor.
Conversely, the American Hospital Association and other advocacy groups for safety-net providers argue that the 340B savings are the "lifeblood" of the vulnerable communities they serve. They contend that cutting these revenues will inevitably lead to service closures, especially in areas where hospitals are already operating on razor-thin margins.
The pharmaceutical industry has largely welcomed the proposal, often lobbying for tighter controls on the 340B program. They argue that the program has been exploited to inflate hospital revenue rather than lower costs for patients. Meanwhile, HHS continues to grapple with the "rebate model" controversy, where companies attempt to replace upfront discounts with post-sale rebates—a model that has been repeatedly stalled by litigation.
The Broader Implications for Safety-Net Healthcare
The proposed 2027 rule does not exist in a vacuum. It arrives alongside the 2025 reconciliation law, which achieved significant federal budget savings through Medicaid cuts. For safety-net hospitals, which are often the primary providers of Medicaid-covered care, the cumulative impact of these policies could be profound.
Financial Viability
Safety-net hospitals already operate with significantly lower margins than their for-profit counterparts. The inability to cross-subsidize their operations through 340B savings may force these institutions to make difficult decisions: deferring infrastructure investments, limiting the number of uninsured patients they treat, or consolidating departments.
Transparency and Future Policy
The growing scrutiny of the 340B program has prompted a bipartisan interest in transparency. Policymakers on both sides of the aisle are pushing for mandatory reporting requirements that would force hospitals to disclose exactly how much they save via 340B and how those dollars are utilized. Some states, such as Minnesota, have already pioneered transparency laws that serve as a blueprint for potential federal legislation.
The Role of Litigation
Given the history of the 2018 policy, observers expect that if the 2027 rule is finalized, it will likely be challenged in court. The central question will be whether the 2026 cost acquisition survey provides a sufficient legal basis for the agency to override the traditional ASP plus 6% standard. As the litigation landscape remains volatile, hospitals and pharmaceutical companies alike are preparing for a protracted legal battle that could reach the Supreme Court once again.
Conclusion: A Delicate Balancing Act
The 2027 Medicare OPPS proposal represents a decisive, if controversial, step toward addressing the criticisms of the 340B program. By attempting to align reimbursement with acquisition costs, CMS is betting that it can lower the cost of healthcare for the Medicare program and for patients.
However, the risk is clear: by withdrawing billions of dollars from the safety-net system, the government may inadvertently weaken the very institutions designed to catch the nation’s most vulnerable citizens. As the comment period closes and the industry waits for the final rule, the debate serves as a stark reminder of the tension between fiscal austerity and the social imperative of equitable healthcare access. The outcome will not only determine the financial future of hospitals across the country but will also define the role of the 340B program in the American healthcare system for years to come.
About the Author
